Class II transactivator: mastering the art of major histocompatibility complex expression.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

84 citing papers in PubMed.

1. Molecular mechanisms of NLR proteins in inflammasome activation.Communications biology · 2026
   Review
2. Targeting pattern recognition receptors for cancer therapy: Mechanisms and strategies.Acta pharmaceutica Sinica. B · 2025
   Review
3. Interferon Regulatory Factors (Genes · 2024
   Article
4. The NLR family of innate immune and cell death sensors.Immunity · 2024
   Review
5. Epstein-Barr virus: the mastermind of immune chaos.Frontiers in immunology · 2024
   Review
6. The NLR gene family: from discovery to present day.Nature reviews. Immunology · 2023
   Review
7. The NLR member CIITA: Master controller of adaptive and intrinsic immunity and unexpected tool in cancer immunotherapy.Biomedical journal · 2023
   Review
8. The quest for effective immunotherapies against malignant peripheral nerve sheath tumors: Is there hope?Molecular therapy oncolytics · 2023
   Review
9. Case report: A late and isolated presentation of meningoencephalomyelitis uncovers a novel pathogenic variant in theFrontiers in pediatrics · 2023
   Article
10. The Immunological Epigenetic Landscape of the Human Life Trajectory.Biomedicines · 2022
    Article
11. The effects of Epigallocatechin-3-gallate and Dabrafenib combination on apoptosis and the genes involved in epigenetic events in anaplastic thyroid cancer cells.Medical oncology (Northwood, London, England) · 2022
    Article
12. Structural aspects of the MHC expression control system.Biophysical chemistry · 2022
    Review
13. CIITA-Transduced Glioblastoma Cells Uncover a Rich Repertoire of Clinically Relevant Tumor-Associated HLA-II Antigens.Molecular & cellular proteomics : MCP · 2021
    Article
14. Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients.International journal of molecular sciences · 2020
    Review
15. Characterization of splenic MRC1Veterinary research · 2020
    Article
16. Recent Advances in Mouse Models of Sjögren's Syndrome.Frontiers in immunology · 2020
    Review
17. Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Review
18. Protective effects of CX3CR1 on autoimmune inflammation in a chronic EAE model for MS through modulation of antigen-presenting cell-related molecular MHC-II and its regulators.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019
    Article
19. Frontiers in immunology · 2019
    Article
20. CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine.Frontiers in immunology · 2019
    Review

24 more citing papers are in PubMed but not listed here.

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as